|
JPH0487425A
(ja)
*
|
1990-07-31 |
1992-03-19 |
Fujitsu Ltd |
回線切り替え装置
|
|
SI1953162T1
(sl)
*
|
2001-02-24 |
2012-09-28 |
Boehringer Ingelheim Pharma |
Ksantinski derivati, njihova priprava in njihova uporaba kot zdravila
|
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
|
ATE537141T1
(de)
*
|
2004-02-05 |
2011-12-15 |
Kyorin Seiyaku Kk |
Bicycloesterderivat
|
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
|
TW200534879A
(en)
*
|
2004-03-25 |
2005-11-01 |
Bristol Myers Squibb Co |
Coated tablet formulation and method
|
|
US20050256314A1
(en)
*
|
2004-05-04 |
2005-11-17 |
Soojin Kim |
Process employing controlled crystallization in forming crystals of a pharmaceutical
|
|
US7829720B2
(en)
*
|
2004-05-04 |
2010-11-09 |
Bristol-Myers Squibb Company |
Process for preparing atazanavir bisulfate and novel forms
|
|
TWI415635B
(zh)
|
2004-05-28 |
2013-11-21 |
必治妥施貴寶公司 |
加衣錠片調製物及製備彼之方法
|
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
|
GB0526291D0
(en)
*
|
2005-12-23 |
2006-02-01 |
Prosidion Ltd |
Therapeutic method
|
|
JP2009526047A
(ja)
*
|
2006-02-09 |
2009-07-16 |
テバ ファーマシューティカル インダストリーズ リミティド |
モンテルカストナトリウムの安定な医薬製剤
|
|
US7915427B2
(en)
*
|
2006-03-08 |
2011-03-29 |
Kyorin Pharmaceuticals Co., Ltd. |
Process for producing aminoacetyl pyrrolidine carbonitrile derivative and intermediate for production thereof
|
|
BRPI0711558A2
(pt)
|
2006-05-04 |
2011-11-08 |
Boeringer Ingelheim Internat Gmbh |
polimorfos
|
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
|
EP1852108A1
(en)
*
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
|
US20070172525A1
(en)
*
|
2007-03-15 |
2007-07-26 |
Ramesh Sesha |
Anti-diabetic combinations
|
|
US20080064701A1
(en)
*
|
2007-04-24 |
2008-03-13 |
Ramesh Sesha |
Anti-diabetic combinations
|
|
TW200904405A
(en)
|
2007-03-22 |
2009-02-01 |
Bristol Myers Squibb Co |
Pharmaceutical formulations containing an SGLT2 inhibitor
|
|
JPWO2008114857A1
(ja)
*
|
2007-03-22 |
2010-07-08 |
杏林製薬株式会社 |
アミノアセチルピロリジンカルボニトリル誘導体の製造方法
|
|
PE20090696A1
(es)
*
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
|
KR20100033378A
(ko)
*
|
2007-06-22 |
2010-03-29 |
브리스톨-마이어스 스큅 컴퍼니 |
아타자나비르를 함유하는 정제 조성물
|
|
PL2170292T3
(pl)
*
|
2007-06-22 |
2014-06-30 |
Bristol Myers Squibb Holdings Ireland |
Tabletkowane kompozycje zawierające atazanawir
|
|
DE602008005462D1
(de)
*
|
2007-06-22 |
2011-04-21 |
Bristol Myers Squibb Co |
Tablettierte atazanavirhaltige zusammensetzungen
|
|
CN101795674A
(zh)
*
|
2007-06-22 |
2010-08-04 |
百时美施贵宝公司 |
含有阿扎那韦的压片组合物
|
|
JP5623275B2
(ja)
*
|
2007-07-31 |
2014-11-12 |
カーギル インコーポレイテッド |
直接打錠可能なデキストロース
|
|
CN105534936B
(zh)
*
|
2007-08-13 |
2020-07-31 |
Ohemo 生命科学股份有限公司 |
抗滥用药物、使用方法和制备方法
|
|
PE20090938A1
(es)
|
2007-08-16 |
2009-08-08 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
|
|
US8551524B2
(en)
*
|
2008-03-14 |
2013-10-08 |
Iycus, Llc |
Anti-diabetic combinations
|
|
PE20140960A1
(es)
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
|
IT1393244B1
(it)
*
|
2008-07-18 |
2012-04-12 |
Universita' Degli Studi Di Milano |
Sistema per il rilascio al colon di farmaci suscettibili di degradazione enzimatica e/o scarsamente assorbiti nel tratto gastrointestinale
|
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
|
BRPI0916997A2
(pt)
|
2008-08-06 |
2020-12-15 |
Boehringer Ingelheim International Gmbh |
Inibidor de dpp-4 e seu uso
|
|
JP5476305B2
(ja)
*
|
2008-08-07 |
2014-04-23 |
杏林製薬株式会社 |
ビシクロ［２．２．２］オクチルアミン誘導体の製造方法
|
|
AU2009282376A1
(en)
*
|
2008-08-12 |
2010-02-18 |
Inspirion Delivery Technologies, Llc |
Pharmaceutical compositions configured to deter dosage form splitting
|
|
US20110152342A1
(en)
*
|
2008-08-14 |
2011-06-23 |
Hiroshi Uchida |
Stabilized pharmaceutical composition
|
|
KR101657960B1
(ko)
|
2008-08-15 |
2016-09-20 |
베링거 인겔하임 인터내셔날 게엠베하 |
Ｆａｂ-관련 질환의 치료에 사용하기 위한 푸린 유도체
|
|
AU2009290911A1
(en)
|
2008-09-10 |
2010-03-18 |
Boehringer Ingelheim International Gmbh |
Combination therapy for the treatment of diabetes and related conditions
|
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
|
DE102008059206A1
(de)
|
2008-11-27 |
2010-06-10 |
Bayer Schering Pharma Aktiengesellschaft |
Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
|
|
EP2382216A1
(en)
|
2008-12-23 |
2011-11-02 |
Boehringer Ingelheim International GmbH |
Salt forms of organic compound
|
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
|
AR075204A1
(es)
|
2009-01-29 |
2011-03-16 |
Boehringer Ingelheim Int |
Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
|
|
WO2010092163A2
(en)
|
2009-02-13 |
2010-08-19 |
Boehringer Ingelheim International Gmbh |
Antidiabetic medications
|
|
MX339194B
(es)
|
2009-02-13 |
2016-05-16 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un inhibidor de sglt2, un inhibidor de dpp-iv y opcionalmente otro agente antidiabetico, y usos de la misma.
|
|
KR20110135411A
(ko)
|
2009-03-27 |
2011-12-16 |
브리스톨-마이어스 스큅 컴퍼니 |
Ｄｐｐ-ｉｖ 억제제로 주요 유해 심장혈관 이벤트를 예방하는 방법
|
|
JPWO2010110436A1
(ja)
|
2009-03-27 |
2012-10-04 |
杏林製薬株式会社 |
塩基性添加剤を含有するマトリックス型徐放性製剤
|
|
JP6088245B2
(ja)
*
|
2009-04-09 |
2017-03-01 |
サンド・アクチエンゲゼルシヤフト |
サクサグリプチンの結晶形態
|
|
CN102711739B
(zh)
|
2009-11-13 |
2015-12-16 |
阿斯利康(瑞典)有限公司 |
双层片剂
|
|
CA3002948C
(en)
*
|
2009-11-13 |
2020-10-27 |
Astrazeneca Uk Limited |
Immediate release tablet formulations
|
|
EA034869B1
(ru)
|
2009-11-27 |
2020-03-31 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
|
|
JP2013522279A
(ja)
|
2010-03-18 |
2013-06-13 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ
|
|
CN102210693B
(zh)
*
|
2010-04-10 |
2013-10-09 |
山东新华制药股份有限公司 |
一种阿司匹林和双嘧达莫多层片的制备方法
|
|
MX341025B
(es)
|
2010-05-05 |
2016-08-04 |
Boehringer Ingelheim Int Gmbh * |
Terapia de combinacion.
|
|
US8501960B2
(en)
|
2010-05-05 |
2013-08-06 |
Assia Chemical Industries Ltd. |
Saxagliptin intermediates, saxagliptin polymorphs, and processes for preparation thereof
|
|
PH12012502524A1
(en)
|
2010-06-24 |
2014-02-10 |
Boehringer Ingelheim Int |
Diabetes therapy
|
|
WO2012017028A1
(en)
|
2010-08-06 |
2012-02-09 |
Sandoz Ag |
A novel crystalline compound comprising saxagliptin and phosphoric acid
|
|
EP2601176A1
(en)
|
2010-08-06 |
2013-06-12 |
Sandoz AG |
Novel salts of saxagrliptin with organic di-acids
|
|
CN103370064A
(zh)
|
2010-09-03 |
2013-10-23 |
百时美施贵宝公司 |
使用水溶性抗氧化剂的药物制剂
|
|
US8410288B2
(en)
|
2010-10-04 |
2013-04-02 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of Saxagliptin hydrochloride and processes for preparing them
|
|
MX366925B
(es)
|
2010-11-04 |
2019-07-31 |
Albireo Ab |
Inhibidores de ibat para el tratamiento de enfermedades hepaticas.
|
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
|
CN102086172A
(zh)
*
|
2011-01-13 |
2011-06-08 |
廖国超 |
沙格列汀的药用盐及其制备方法
|
|
AU2012212448B9
(en)
*
|
2011-02-01 |
2015-06-25 |
Astrazeneca Uk Limited |
Pharmaceutical formulations including an amine compound
|
|
EP3517539B1
(en)
|
2011-07-15 |
2022-12-14 |
Boehringer Ingelheim International GmbH |
Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
|
|
KR20140057604A
(ko)
|
2011-08-12 |
2014-05-13 |
베링거잉겔하임베트메디카게엠베하 |
고양잇과 동물의 심부전을 치료 및 예방하는 방법에 사용하기 위한 퍼니 전류 억제제
|
|
EP2753328A1
(en)
|
2011-09-07 |
2014-07-16 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Dpp-iv inhibitor formulations
|
|
US9446000B2
(en)
|
2011-09-08 |
2016-09-20 |
Masdar Institute Of Science And Technology |
Cellulosic gel material as a pharmaceutical excipient
|
|
PL2578208T3
(pl)
|
2011-10-06 |
2014-10-31 |
Sanovel Ilac Sanayi Ve Ticaret As |
Stałe formulacje dawkowane inhibitora DPP-IV
|
|
WO2013106526A1
(en)
|
2012-01-10 |
2013-07-18 |
Teva Pharmaceutical Industries Ltd. |
Saxagliptin parmaceutical formulations
|
|
WO2013130785A2
(en)
|
2012-03-01 |
2013-09-06 |
Bristol-Myers Squibb Company |
Extended release pharmaceutical formulations of water-soluble active pharmaceutical ingredients and methods for making the same
|
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
|
WO2013167453A1
(en)
|
2012-05-07 |
2013-11-14 |
Bayer Pharma Aktiengesellschaft |
Process for manufacturing a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil
|
|
JP6224084B2
(ja)
|
2012-05-14 |
2017-11-01 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
|
|
US20130303554A1
(en)
|
2012-05-14 |
2013-11-14 |
Boehringer Ingelheim International Gmbh |
Use of a dpp-4 inhibitor in sirs and/or sepsis
|
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
|
WO2013179307A2
(en)
*
|
2012-05-29 |
2013-12-05 |
Mylan Laboratories Limited |
Stabilized pharmaceutical compositions of saxagliptin
|
|
WO2014030051A1
(en)
|
2012-08-23 |
2014-02-27 |
Aurobindo Pharma Limited |
Stable pharmaceutical compositions comprising saxagliptin
|
|
WO2014065427A1
(ja)
*
|
2012-10-26 |
2014-05-01 |
株式会社 三和化学研究所 |
アナグリプチン含有固形製剤
|
|
WO2014096983A1
(en)
|
2012-12-21 |
2014-06-26 |
Wockhardt Limited |
Stable pharmaceutical compositions of saxagliptin or salts thereof
|
|
WO2014096982A1
(en)
|
2012-12-21 |
2014-06-26 |
Wockhardt Limited |
Stable pharmaceutical compositions of saxagliptin or salts thereof
|
|
US20140275038A1
(en)
|
2013-03-15 |
2014-09-18 |
Inspirion Delivery Technologies, Llc |
Abuse deterrent compositions and methods of use
|
|
WO2014193528A1
(en)
*
|
2013-04-29 |
2014-12-04 |
Anovel Pharmaceuticals, Llc |
Amorphous dosage forms and methods
|
|
CN103316056B
(zh)
*
|
2013-06-24 |
2015-07-08 |
江苏鹏鹞药业有限公司 |
一种板蓝根包衣分散片及其制备方法
|
|
WO2015071887A1
(en)
|
2013-11-18 |
2015-05-21 |
Ranbaxy Laboratories Limited |
Oral pharmaceutical compositions of saxagliptin
|
|
WO2015071889A1
(en)
|
2013-11-18 |
2015-05-21 |
Ranbaxy Laboratories Limited |
Oral compositions of saxagliptin
|
|
CA2933202C
(en)
|
2014-01-21 |
2022-05-31 |
Jason Teckoe |
Immediate release film coatings containing medium chain glycerides and substrates coated therewith
|
|
US9526728B2
(en)
|
2014-02-28 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Medical use of a DPP-4 inhibitor
|
|
CA2952406A1
(en)
*
|
2014-06-25 |
2015-12-30 |
Ea Pharma Co., Ltd. |
Solid formulation and method for preventing or reducing coloration thereof
|
|
US10729685B2
(en)
|
2014-09-15 |
2020-08-04 |
Ohemo Life Sciences Inc. |
Orally administrable compositions and methods of deterring abuse by intranasal administration
|
|
CN105520913B
(zh)
*
|
2014-09-28 |
2020-06-23 |
石药集团中奇制药技术（石家庄）有限公司 |
一种包含沙格列汀的微丸、其用途及其制备方法
|
|
CN105497023B
(zh)
*
|
2014-10-15 |
2021-05-25 |
北京福元医药股份有限公司 |
一种沙格列汀药物制剂
|
|
EP3012252A1
(en)
|
2014-10-24 |
2016-04-27 |
Ferring BV |
Crystal modifications of elobixibat
|
|
CN104557943B
(zh)
*
|
2014-12-23 |
2017-05-03 |
扬子江药业集团四川海蓉药业有限公司 |
一种维格列汀杂质的制备方法
|
|
CN105796503B
(zh)
*
|
2014-12-30 |
2019-05-07 |
深圳翰宇药业股份有限公司 |
一种沙格列汀微丸及其制剂
|
|
CN104672243B
(zh)
*
|
2015-02-10 |
2017-09-22 |
华润赛科药业有限责任公司 |
维格列汀降解杂质的制备方法
|
|
US20160287573A1
(en)
|
2015-04-02 |
2016-10-06 |
Theravance Biopharma R&D Ip, Llc |
Combination dosage form of a mu opioid receptor antagonist and an opioid agent
|
|
CN106176661B
(zh)
*
|
2015-04-29 |
2019-02-01 |
四川科伦药物研究院有限公司 |
一种沙格列汀或其盐的胶囊及其制备方法
|
|
TWI804919B
(zh)
*
|
2015-06-30 |
2023-06-11 |
美商建南德克公司 |
含藥物之立即釋放錠劑及形成該錠劑的方法
|
|
CN106924207A
(zh)
*
|
2015-12-31 |
2017-07-07 |
深圳翰宇药业股份有限公司 |
一种维格列汀片剂及其制备方法
|
|
CA3011595C
(en)
|
2016-02-09 |
2024-01-02 |
Albireo Ab |
Cholestyramine pellets and methods for preparation thereof
|
|
CN108601744B
(zh)
|
2016-02-09 |
2022-01-04 |
阿尔比里奥公司 |
口服考来烯胺制剂及其用途
|
|
JP6954927B2
(ja)
|
2016-02-09 |
2021-10-27 |
アルビレオ・アクチボラグ |
経口コレスチラミン製剤及びその使用
|
|
CN109310697A
(zh)
|
2016-06-10 |
2019-02-05 |
勃林格殷格翰国际有限公司 |
利格列汀和二甲双胍的组合
|
|
CN111032019B
(zh)
|
2017-08-09 |
2022-07-05 |
阿尔比里奥公司 |
考来烯胺颗粒、口服考来烯胺制剂及其用途
|
|
CN108822820B
(zh)
*
|
2018-05-22 |
2020-11-03 |
东莞理工学院 |
一种隔离型水合物动力学抑制胶囊及其制备方法与应用
|
|
JP7391048B2
(ja)
|
2018-06-05 |
2023-12-04 |
アルビレオ・アクチボラグ |
ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
|
|
KR20210024033A
(ko)
|
2018-06-20 |
2021-03-04 |
알비레오 에이비 |
오데빅시바트의 약학 제제
|
|
US11801226B2
(en)
|
2018-06-20 |
2023-10-31 |
Albireo Ab |
Pharmaceutical formulation of odevixibat
|
|
US11007142B2
(en)
|
2018-08-09 |
2021-05-18 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
US11549878B2
(en)
|
2018-08-09 |
2023-01-10 |
Albireo Ab |
In vitro method for determining the adsorbing capacity of an insoluble adsorbant
|
|
US10722457B2
(en)
|
2018-08-09 |
2020-07-28 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
WO2020098904A1
(en)
|
2018-11-12 |
2020-05-22 |
Pharmaceutical Oriented Services Ltd |
Dosage form containing metformin and a dipeptidyl peptidase iv inhibitor
|
|
CN113453753B
(zh)
|
2019-02-06 |
2024-07-23 |
阿尔比里奥公司 |
苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
|
|
SG11202108566VA
(en)
|
2019-02-06 |
2021-09-29 |
Albireo Ab |
Benzothiadiazepine compounds and their use as bile acid modulators
|
|
CN109999006A
(zh)
*
|
2019-04-28 |
2019-07-12 |
江苏豪森药业集团有限公司 |
沙格列汀包衣片及其制备方法
|
|
CA3158181A1
(en)
|
2019-12-04 |
2021-06-10 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
JP7665621B2
(ja)
|
2019-12-04 |
2025-04-21 |
アルビレオ・アクチボラグ |
ベンゾチアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
|
|
CA3158195A1
(en)
|
2019-12-04 |
2021-06-10 |
Per-Goran Gillberg |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
CN114786772B
(zh)
|
2019-12-04 |
2024-04-09 |
阿尔比里奥公司 |
苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
|
|
WO2021110885A1
(en)
|
2019-12-04 |
2021-06-10 |
Albireo Ab |
Benzothiadiazepine compounds and their use as bile acid modulators
|
|
JP7514121B2
(ja)
|
2020-06-23 |
2024-07-10 |
沢井製薬株式会社 |
サキサグリプチン含有製剤及びその製造方法
|
|
ES3002777T3
(en)
|
2020-08-03 |
2025-03-07 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
AU2021379076A1
(en)
|
2020-11-12 |
2023-06-08 |
Albireo Ab |
Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
|
|
BR112023010799A2
(pt)
|
2020-12-04 |
2023-10-03 |
Albireo Ab |
Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares
|
|
JP2022135147A
(ja)
*
|
2021-03-04 |
2022-09-15 |
日医工株式会社 |
サキサグリプチン含有錠剤
|
|
CN117412955A
(zh)
|
2021-06-03 |
2024-01-16 |
阿尔比里奥公司 |
苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
|
|
KR20220165346A
(ko)
|
2021-06-08 |
2022-12-15 |
동아에스티 주식회사 |
에보글립틴의 안정성이 개선된 제제
|